loader2
Partner With Us NRI

Biocon Ltd share Price Today

Company details

259.20
266.75
199.65
307.10
6M Return -0.19%
1Y Return 27.82%
Mkt Cap.(Cr) 31,713.85
Volume 7,744,310
Div Yield 0.57%
OI
-
OI Chg %
-
Volume 7,744,310

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500
Steady performance; focus on Viatris integration...
About The Stock

     Biocon mainly operates in biologics (biosimilars), small molecules (generics), branded formulations and contract research (Syngene). Biocon Biologics (BBL), a subsidiary of Biocon, entered into an arrangement to acquire Viatris’ biosimilars assets for US$3.335 billion. Biocon Biologics entered into a strategic alliance with SILS for access to 100 million vaccine doses per annum for 15 years.

    • Biosimilar US pipeline: (approvals - Pegfilgrastim, Trastuzumab, Glargine, Adalimumab); filed - Aspart and Bevacizumab
    • In generics, it is among the world’s largest manufacturers of immunosuppressant and statin APIs
    • Revenue breakup FY22: Biosimilars (41%), Generics (28%), CRAMS (31%)
Q4FY22

    Biocon reported strong revenues driven by all three segments.

    • Revenue was up 31% YoY to ₹ 2409 crore
    • EBITDA in Q4FY22 was ₹ 592 crore, up 36% YoY with margins at 24.6%
    • Consequent adjusted PAT was at ₹ 239 crore (down 6% YoY)

Click here for full recommendation

Research view on more stocks

Biotechnology company Biocon announced Q3FY24 results:

  • Consolidated Revenue for Q3FY24 grew 50% YoY to Rs 4,519 crore. This growth was supported by income from the divesture of two non-core business assets of Biocon Biologics' Branded Formulations India business amounting to Rs 350 crore and a gain of Rs 456 crore from Biocon’s stake dilution in Bicara Therapeutics.
  • EBITDA for the quarter increased by 106% to Rs 1,492 crore, representing an EBITDA margin of 33% versus 24% in the same period last year.
  • Depreciation, amortisation, and interest increased by Rs 260 crore last year. This is primarily related to the biosimilars business acquisition cost.
  • Net R&D investments for the quarter were Rs 329 crore, representing 11% of revenue exSyngene.
  • Core EBITDA at Rs 983 crore, represents core operating margins of 27%.
  • Profit Before Tax and exceptional items stood at Rs 787 crore.
  • Reported Net Profit for the quarter stood at Rs 660 crore versus a Net Loss of Rs 42 crore in the same quarter of the previous year.

"Biocon delivered Consolidated Revenue of Rs 4,519 crore for Q3FY24, driven by 65% growth in Biosimilars and 9% growth in Research Services. Consolidated EBITDA at Rs 1,492 crore grew by 106%. Net Profit, boosted by other income, stood at Rs 660 crore.

A key milestone this quarter was the successful conclusion of the transition of the acquired business by Biocon Biologics and a pre-payment of ~USD 200 million towards the acquisition-related debt reduction. Steady market shares for key biosimilars in the U.S. and EU were complemented by the Emerging Markets performance which saw a number of new product launches and tender wins.

We continue to make steady progress towards strengthening the foundation for sustainable growth across all three business segments”,  Kiran Mazumdar Shaw, Executive Chairperson, Biocon and Biocon Biologics.

“The Generics business delivered 4% sequential revenue growth in the third quarter, driven by higher API sales.

The year-on-year performance, however, was muted on account of continued pricing pressure that impacted customer offtake in our API business, compared to the previous fiscal. This was partially offset by growth in our Generic Formulations portfolio. While we expect pricing pressure in the API business to persist, we continue focusing on driving cost and execution efficiencies throughout the business, to mitigate future impact.

We received a tentative approval of our ANDA for Dasatinib tablets from the U.S. FDA recently, which reinforces our strategy to vertically integrate complex, difficult-to-make products”, Siddharth Mittal, CEO & Managing Director, Biocon.

Result PDF

View Other Company Results

Biocon Ltd shares SWOT Analysis

Strengths (9)

  • Rising Net Cash Flow and Cash from Operating activity
  • Good quarterly growth in the recent results
  • Companies with rising net profit margins - quarterly as well as TTM basis

Weakness (4)

  • Inefficient use of capital to generate profits - RoCE declining in the last 2 years
  • Inefficient use of shareholder funds - ROE declining in the last 2 years
  • Inefficient use of assets to generate profits - ROA declining in the last 2 years

Opportunity (1)

  • Companies with current TTM PE Ratio less than 3 Year, 5 Year and 10 Year PE

Threats (2)

  • Companies Increasing Debt as per Annual Report
  • Increasing Trend in Non-Core Income

Resistance and support

R1 267.5
R2 270.9
R3 275.1
Pivot

263.37

S1 260.0
S2 255.8
S3 252.4
EMA SMA
261.8
265.6
262.9
260.0
264.3
270.5
259.6
257.2
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
THE JUPITER GLOBAL FUND-JUPITER INDIA SELECT Block Purchase 2024-01-18 279.8 469049 BSE
JUPITER SOUTH ASIA INVESTMENT COMPANY LIMITED Block Sell 2024-01-18 279.8 469049 BSE
AHAN - I LTD Bulk Sell 2023-03-17 200.74 18928363 NSE
Name Category Shares
KIRAN MAZUMDAR SHAW PROMOTER 40.36%
GLENTEC INTERNATIONAL PROMOTER 19.76%

OUR RESEARCH VIEW

Investment recommendation
Steady performance; focus on Viatris integration...
Call Date
16 Feb 2023
Entry Price 241.00
Target Price 230.00
Duration
12-18 Month

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Biocon Ltd Stocks COMPARISON

Financials( in Cr) Biocon Ltd Sun Pharmaceuticals Industries Ltd Cipla Ltd Dr Reddys Laboratories Ltd Zydus Lifesciences Ltd
Price 264.15 1,620.55 1,496.95 6,157.90 1,007.35
% Change 2.94 1.02 2.30 1.88 0.77
Mcap Cr 31,713.85 388,824.23 120,856.26 102,719.31 101,964.37
Revenue TTM Cr 11,174.20 43,885.68 15,790.60 24,669.70 17,237.40
Net Profit TTM Cr 643.00 8,560.84 2,513.47 4,507.30 1,997.30
PE TTM 26.38 41.45 30.52 19.64 30.51
1 Year Return 27.82 64.78 68.33 37.28 109.04
ROCE 5.68 16.79 14.76 25.99 16.25
ROE 6.64 16.46 10.66 21.21 14.05
INSIDER & INSTITUIONAL ACTIVITY

Equity Capital: 17,866.90 Cr FV: 5.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 29,068.81 33,709.58
LAST 3M 68,518.10 30,558.15
LAST 6M 130,081.93 64,349.19
LAST 12M 189,941.35 208,211.24
Biocon Limited - Trading Window

Mar 28, 2024 l NSE Announcement

Biocon Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Mar 26, 2024 l NSE Announcement

Biocon Limited - Updates

Mar 22, 2024 l NSE Announcement

Date Action Type Ratio
Jul 07, 2023 Dividend 30
Jun 30, 2022 Dividend 10

Biocon Ltd Information

Stock PE (TTM)
26.38
Promoter Holding
60.64%
Book Value
158.1001
ROCE
5.68%
ROE
6.64%
Registered Address

20th KM Hosur Road Hebbagodi, Electronic City P O, Bangalore, Karnataka, 560100

Tel : 91-80-28082808
Email : co.secretary:biocon.com
Website : http://www.biocon.com
Registrar

Karvy Computershare Pvt Ltd

AGM Date (Month) : Aug
Face Value Equity Shares : 5
Market Lot Equity Shares : 1
BSE Code : 532523
NSE Code : BIOCON
Book Closure Date (Month) :
BSE Group : A
ISIN : INE376G01013

FAQ’s on Biocon Ltd Shares

You can buy Biocon Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Biocon Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Mar 28, 2024 04:09 PM the closing price of Biocon Ltd was ₹ 264.15.

Market capitalization or market cap is determined by multiplying the current market price of a company’s shares with the total number of shares outstanding. As of Mar 28, 2024 04:09 PM, the market cap of Biocon Ltd stood at ₹ 31,713.85.

The latest PE ratio of Biocon Ltd as of Mar 28, 2024 04:09 PM is 26.38

The latest PB ratio of Biocon Ltd as of Mar 28, 2024 04:09 PM is 0.60

The 52-week high of Biocon Ltd share price is ₹ 307.10 while the 52-week low is ₹ 199.65

According to analyst recommendations, Biocon Ltd Share has a “Buy” rating for the long term.

Download Our

Download App
market app